Spectrum To Test Poziotinib's Potential As First Line Treatment Of Exon 20 Mutant NSCLC

 
• By Jung Won Shin
  
Neon Light Sign Lungs Icon
Poziotinib trials expanded to first-line EGFR or HER2 Exon 20 mutant NSCLC • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D